Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235235 · ClinicalTrials.gov registry record
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 80
- Enrollment target
NCT00235235: Clinical Trial study, sponsored by Hoosier Cancer Research Network.
NCT00235235 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235235 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, the researchers expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, the researchers expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Interventions
- DRUG Cyclophosphamide
- PROCEDURE Biopsy
- DRUG Doxorubicin
- PROCEDURE Serum Collection
- PROCEDURE Urine Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-12 |
Why NCT00235235 stopped before completion
NCT00235235 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00235235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00235235 about?
NCT00235235 is a clinical study titled "A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer". The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. To date no other trial has analyzed gene and protein expression at the same time points in ...
What is the current status of trial NCT00235235?
This trial is currently terminated. The enrollment target is 80 participants. The study started on 2005-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00235235?
The interventions under investigation include: Cyclophosphamide (DRUG), Biopsy (PROCEDURE), Doxorubicin (DRUG), Serum Collection (PROCEDURE), Urine Collection (PROCEDURE).
Who is sponsoring clinical trial NCT00235235?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia